USPTO Grants Interim Patent Term Extension for Centanafadine Hydrochloride

WISECODE Take

Many business owners view patent expiration as a hard whistle ending the game. However, in highly regulated R&D sectors, the rules allow for "injury time" to extend the play. The USPTO recently granted a one-year interim extension for U.S. Patent No. 8,461,196, covering Centanafadine Hydrochloride. This mechanism acts like a referee adding extra time during regulatory delays, preventing the innovator's hard-earned lead from vanishing instantly. For businesses, this overtime is a golden window to safeguard market exclusivity. Failing to plan for extensions is like walking off the field early, handing your defense over to competitors. To secure victory in overtime, I suggest two actions. First, closely align regulatory timelines with patent terms. Second, systematically audit whether core technologies qualify for term extensions. Patent strategy is a marathon where the finish line can be extended. Zhidian offers patent portfolio health checks to help you master the pace, though specific extension strategies should be assessed through consultation.